New rhodol-sulforaphane conjugates as innovative isothiocyanate-based cytotoxic agents for cancer cells

Andrea Milelli, Elena Catanzaro, Giulia Greco, Cinzia Calcabrini, Eleonora Turrini, Francesca Maffei, Sabrina Burattini, Melissa Guardigni, Claudia Sissi, Michael Schnekenburger, Marc Diederich, Piero Sestili*, Carmela Fimognari*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

In search of semisynthetic derivatives with increased antitumor activity, we condensed sulforaphane (SFR) with rhodol, a fluorophore platform capable of modifying the intracellular trafficking and pharmacokinetics of the linked molecules. The two tested derivatives, namely MG28 and MG46, showed a far higher, as compared to SFR, cytotoxicity toward cancer cells. Apoptotic cell death was preceded by the extensive generation of DNA lesions, which were repaired relatively slowly and caused formation of micronuclei. Unlike SFR, rhodol-SFR conjugates’ DNA lesions resulted from direct interactions with nuclear DNA. Overall, MG28 and MG46 exhibit a remarkable cytotoxic effect, which is the likely consequence of their direct and intense DNA damaging activity, i.e., a novel and peculiar mechanism arising from the conjugation of the parental rhodol and SFR. Considering that a wide number of clinically used drugs kill cancer cells by inducing DNA damage, MG could represent a new and promising chance in antitumor chemotherapy.

Original languageEnglish
Article number116936
JournalEuropean Journal of Medicinal Chemistry
Volume280
DOIs
Publication statusPublished - 15 Dec 2024
Externally publishedYes

Keywords

  • Anticancer agents
  • Cytotoxicity
  • DNA damage
  • Isothiocyanates
  • Rhodol
  • Sulforaphane

Fingerprint

Dive into the research topics of 'New rhodol-sulforaphane conjugates as innovative isothiocyanate-based cytotoxic agents for cancer cells'. Together they form a unique fingerprint.

Cite this